Open AccessP014 Postoperative Recurrence in Crohn’s Disease Patients Treated with Adalimumab versus Infliximab: A Systematic Review and Meta-Analysis
Author(s) -
Frankl Luke,
Tarakji Ahmad,
Shintaro Akiyama,
Hennawi Hussam,
Alexander Levy,
Shadi Hamdeh
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000798656.34221.7f
Subject(s) - medicine , adalimumab , infliximab , meta analysis , crohn's disease , adverse effect , odds ratio , surgery , incidence (geometry) , disease , physics , optics
Up to 80% of patients with Crohn's disease (CD) undergo intestinal resection at one point. However, the risk of post-operative recurrence (POR) increases with time, with half of these patients developing recurrence at five years after surgery. Treatment with anti-tumor necrosis factor (anti-TNF) agents has been shown to decrease the risk of clinical and endoscopic recurrence post-operatively. This meta-analysis aims to compare the rate of the two mostly commonly used anti-TNF agents (infliximab (IFX) and adalimumab (ADA)) and their efficacy in maintaining clinical and endoscopic remission in CD patients who were treated with adalimumab versus infliximab after surgery.